Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death Simendra Singh Review Article 21 August 2014 Pages: 1 - 15
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer H. S. HochsterN. UbohaL. Leichman Original Article 17 October 2014 Pages: 17 - 23
Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer H. S. HochsterN. UbohaH.-J. Lenz Erratum 02 December 2014 Pages: 25 - 25
Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections Karen D. WrightJohn C. PanettaClinton F. Stewart Original Article 24 October 2014 Pages: 27 - 35
A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study Yvonne WettergrenHelena TaflinKristoffer Derwinger Original Article Open access 24 October 2014 Pages: 37 - 47
Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing Kouichi InoueAkira ShishidoCaly Chien Original Article 25 October 2014 Pages: 49 - 58
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity Mette LevinsenSusanne RosthøjKjeld Schmiegelow Original Article 28 October 2014 Pages: 59 - 66
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration Jeannine S. McCunePaolo ViciniDonald E. Mager Original Article 06 November 2014 Pages: 67 - 75
Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery Hyun-ju LimHo Yun LeeYoung Mog Shim Original Article 06 November 2014 Pages: 77 - 85
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function Sunil SharmaPetronella O. WitteveenSong Mu Original Article 07 November 2014 Pages: 87 - 95
Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies Yook-Hwan NohHyeong-Seok LimKyun-Seop Bae Original Article 07 November 2014 Pages: 97 - 109
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies Eleonora MarosticaJuthamas SukbuntherngItalo Poggesi Original Article 08 November 2014 Pages: 111 - 121
Atrial natriuretic peptide protects against cisplatin-induced acute kidney injury Takashi NojiriHiroshi HosodaKenji Kangawa Original Article 11 November 2014 Pages: 123 - 129
TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts Jamie L. CroucherRadhika IyerGarrett M. Brodeur Original Article 14 November 2014 Pages: 131 - 141
Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews Julie L. EisemanJan H. BeumerCharles C. Horn Original Article 15 November 2014 Pages: 143 - 152
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer E. KontopodisN. KentepozidisD. Mavroudis Original Article 15 November 2014 Pages: 153 - 160
Biological evaluation of a novel sorafenib analogue, t-CUPM Aaron T. WeckslerSung Hee HwangBruce D. Hammock Original Article 21 November 2014 Pages: 161 - 171
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor Dong-Hoe KooMin-Hee RyuYoon-Koo Kang Original Article 23 November 2014 Pages: 173 - 182
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma Anthony W. TolcherAmita PatnaikMark Cornfeld Original Article 25 November 2014 Pages: 183 - 189
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer Tadashi UwagawaTaro SakamotoKatsuhiko Yanaga Original Article 25 November 2014 Pages: 191 - 196
EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation Dong-Hoe KooKyu-pyo KimSang-We Kim Original Article 25 November 2014 Pages: 197 - 206
Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer F. HarounL. Al-ShaarN. K. Zgheib Original Article 27 November 2014 Pages: 207 - 214
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors Julien EdelineLaurence CrouzetEveline Boucher Short Communication 05 December 2014 Pages: 215 - 219